

Piercarlo Sarzi-Puttini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6546016/publications.pdf>

Version: 2024-02-01

326
papers

14,759
citations

19657

61
h-index

28297

105
g-index

335
all docs

335
docs citations

335
times ranked

15746
citing authors

#	ARTICLE	IF	CITATIONS
1	Definition of fibromyalgia severity: findings from a cross-sectional survey of 2339 Italian patients. <i>Rheumatology</i> , 2021, 60, 728-736.	1.9	15
2	Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. <i>Joint Bone Spine</i> , 2021, 88, 105062.	1.6	14
3	Differences in depression, anxiety and stress disorders between fibromyalgia associated with rheumatoid arthritis and primary fibromyalgia. <i>Stress and Health</i> , 2021, 37, 255-262.	2.6	5
4	Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study. <i>Journal of Autoimmunity</i> , 2021, 116, 102545.	6.5	25
5	The association between body mass index and fibromyalgia severity: data from a cross-sectional survey of 2339 patients. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab015.	0.7	5
6	Clinimetrics of Fibromyalgia Syndrome. , 2021, , 223-243.		0
7	Diffuse Idiopathic Skeletal Hyperostosis (DISH) and a Possible Inflammatory Component. <i>Current Rheumatology Reports</i> , 2021, 23, 6.	4.7	32
8	Comparison of Efficacy of Ketoprofen and Ibuprofen in Treating Pain in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. <i>Pain and Therapy</i> , 2021, 10, 577-588.	3.2	14
9	Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry. <i>Clinical Rheumatology</i> , 2021, 40, 4039-4047.	2.2	3
10	Cannabis and Autoimmunity: Possible Mechanisms of Action. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 261-271.	5.8	14
11	Presence of specific T cell response after SARS-CoV-2 vaccination in rheumatoid arthritis patients receiving rituximab. <i>Immunologic Research</i> , 2021, 69, 309-311.	2.9	21
12	Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3050-3055.	2.8	16
13	Psoriatic Arthritis and Metabolic Syndrome: Is There a Role for Disease Modifying Anti-Rheumatic Drugs?. <i>Frontiers in Medicine</i> , 2021, 8, 735150.	2.6	8
14	The Italian Society for Rheumatology clinical practice guidelines for the diagnosis and management of fibromyalgia. Best practices based on current scientific evidence. <i>Reumatismo</i> , 2021, 73, 89-105.	0.9	8
15	Intestinal microbiota changes induced by TNF-inhibitors in IBD-related spondyloarthritis. <i>RMD Open</i> , 2021, 7, e001755.	3.8	12
16	Predicting Severe/Critical Outcomes in Patients With SARS-CoV2 Pneumonia: Development of the prediction severe/critical outcome in COVID-19 (CRITIC) Model. <i>Frontiers in Medicine</i> , 2021, 8, 695195.	2.6	8
17	Covid vaccination in patients with autoimmune diseases treated with mycophenolate: Let's think back to the recommendations. <i>Autoimmunity Reviews</i> , 2021, 20, 102908.	5.8	1
18	Acetyl-L-carnitine in chronic pain: A narrative review. <i>Pharmacological Research</i> , 2021, 173, 105874.	7.1	18

#	ARTICLE	IF	CITATIONS
19	Rheumatoid Arthritis disease activity assessment in routine care: performance of the most widely used composite disease activity indices and patient-reported outcome measures. <i>Acta Biomedica</i> , 2021, 92, e2021238.	0.3	1
20	Vaccination against SARS-CoV-2 in patients with rheumatic diseases: doubts and perspectives. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 196-202.	0.8	6
21	Use of rituximab in a multicentre cohort of patients with rheumatic diseases during the outbreak of novel SARS-COV-2 infection. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 695.	0.8	0
22	One year in review 2021: fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 3-12.	0.8	32
23	Use of rituximab in a multicentre cohort of patients with rheumatic diseases during the outbreak of novel SARS-COV-2 infection. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 695-695.	0.8	1
24	Predictive validity of the 5-item Compliance Questionnaire for Rheumatology (CQR5) in detecting poor adherence of patients with rheumatoid arthritis to biological medication. <i>Arthritis Research and Therapy</i> , 2020, 22, 227.	3.5	3
25	The role of a chest computed tomography severity score in coronavirus disease 2019 pneumonia. <i>Medicine (United States)</i> , 2020, 99, e22433.	1.0	30
26	Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. <i>Nature Reviews Rheumatology</i> , 2020, 16, 645-660.	8.0	279
27	The Co-Morbidity between Bipolar and Panic Disorder in Fibromyalgia Syndrome. <i>Journal of Clinical Medicine</i> , 2020, 9, 3619.	2.4	3
28	How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion. <i>Autoimmunity Reviews</i> , 2020, 19, 102574.	5.8	32
29	Study of entheses in patients with spondyloarthritis and inflammatory bowel disease with and without fibromyalgia: The importance of ultrasonography. <i>Joint Bone Spine</i> , 2020, 87, 507-508.	1.6	2
30	Toxicological considerations in the treatment of axial spondylo-arthritis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 663-672.	3.3	1
31	Chest CT features of coronavirus disease 2019 (COVID-19) pneumonia: key points for radiologists. <i>Radiologia Medica</i> , 2020, 125, 636-646.	7.7	165
32	Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors. <i>Autoimmunity Reviews</i> , 2020, 19, 102509.	5.8	13
33	Diagnosis of fibromyalgia: comparison of the 2011/2016 ACR and AAPT criteria and validation of the modified Fibromyalgia Assessment Status. <i>Rheumatology</i> , 2020, 59, 3042-3049.	1.9	33
34	What is the role of rheumatologists in the era of COVID-19?. <i>Autoimmunity Reviews</i> , 2020, 19, 102539.	5.8	25
35	Extra-intestinal manifestations of inflammatory bowel diseases. <i>Pharmacological Research</i> , 2020, 161, 105206.	7.1	22
36	Cardiovascular Consequences of Autoimmune Rheumatic Diseases. <i>Current Vascular Pharmacology</i> , 2020, 18, 566-579.	1.7	13

#	ARTICLE	IF	CITATIONS
37	Assessment of enthesitis in patients with psoriatic arthritis and fibromyalgia using clinical examination and ultrasound. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 123, 31-39.	0.8	9
38	Adding medical cannabis to standard analgesic treatment for fibromyalgia: a prospective observational study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 123, 53-59.	0.8	6
39	Exercise therapy in fibromyalgia patients: comparison of a web-based intervention with usual care. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 123, 86-93.	0.8	1
40	COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 337-342.	0.8	249
41	The therapeutic journey of biologic agents: There will be an end?. <i>Pharmacological Research</i> , 2019, 147, 104340.	7.1	3
42	Noninvasive imaging methods for evaluating cardiovascular involvement in patients with rheumatoid arthritis before and after anti-TNF drug treatment. <i>Future Science OA</i> , 2019, 5, FSO396.	1.9	9
43	Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents. <i>Autoimmunity Reviews</i> , 2019, 18, 102398.	5.8	75
44	Biosimilars vs originators: Are they the same?. <i>Autoimmunity Reviews</i> , 2019, 18, 102404.	5.8	6
45	Cannabinoids in the treatment of rheumatic diseases: Pros and cons. <i>Autoimmunity Reviews</i> , 2019, 18, 102409.	5.8	26
46	Medical cannabis and cannabinoids in rheumatology: where are we now?. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 1019-1032.	3.0	20
47	Psoriatic arthritis: From pathogenesis to pharmacologic management. <i>Pharmacological Research</i> , 2019, 148, 104394.	7.1	16
48	Recommendations for managing the manifestations of severe and life-threatening mixed cryoglobulinemia syndrome. <i>Autoimmunity Reviews</i> , 2019, 18, 778-785.	5.8	32
49	Biologics and Biosimilars. , 2019, , 625-628.		0
50	Systemic rheumatic diseases: From biological agents to small molecules. <i>Autoimmunity Reviews</i> , 2019, 18, 583-592.	5.8	64
51	Response to Wolfe. Letter to the Editor, "Fibromyalgia Criteria", <i>Journal of Pain</i> , 2019, 20, 741-742.	1.4	2
52	Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2019, 29, 895-902.	1.8	9
53	AAPT Diagnostic Criteria for Fibromyalgia. <i>Journal of Pain</i> , 2019, 20, 611-628.	1.4	222
54	Fibromyalgia syndrome: under-, over- and misdiagnosis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 116, 90-97.	0.8	25

#	ARTICLE	IF	CITATIONS
55	Fibromyalgia and the concept of resilience. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 116, 105-113.	0.8	13
56	Hyperbaric oxygen treatment of fibromyalgia: a prospective observational clinical study. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 116, 63-69.	0.8	3
57	Comparison of methods and TAT assessment: Volumetric AQUIOS CL and bead-based FACS CANTO II cytometers. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 674-678.	1.5	6
58	Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics register GISEA. <i>Clinical Rheumatology</i> , 2018, 37, 315-321.	2.2	37
59	Features of mood associated with high body weight in females with fibromyalgia. <i>Comprehensive Psychiatry</i> , 2018, 80, 57-64.	3.1	8
60	Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs. <i>Joint Bone Spine</i> , 2018, 85, 455-459.	1.6	14
61	Controversies in Rheumatology and Autoimmunity: Approaching the truth by the discussion. <i>Autoimmunity Reviews</i> , 2018, 17, 1-3.	5.8	2
62	TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same?. <i>Autoimmunity Reviews</i> , 2018, 17, 24-28.	5.8	39
63	Are the ACR 2010 diagnostic criteria for fibromyalgia better than the 1990 criteria?. <i>Autoimmunity Reviews</i> , 2018, 17, 33-35.	5.8	40
64	Anti-tumour necrosis factor antibodies and B cell homeostasis in human inflammatory bowel diseases. <i>International Immunopharmacology</i> , 2018, 54, 329-335.	3.8	8
65	Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 69-82.	3.0	64
66	The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference. <i>Rheumatology</i> , 2018, 57, vii11-vii22.	1.9	17
67	Neurobiological similarities between RA and fibromyalgia. <i>Nature Reviews Rheumatology</i> , 2018, 14, 324-325.	8.0	0
68	The subjective components of the Disease Activity Score 28-joints (DAS28) in rheumatoid arthritis patients and coexisting fibromyalgia. <i>Rheumatology International</i> , 2018, 38, 1911-1918.	3.0	23
69	Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 945-956.	3.0	16
70	Cardiovascular Imaging Techniques in Systemic Rheumatic Diseases. <i>Frontiers in Medicine</i> , 2018, 5, 26.	2.6	7
71	Conventional and Biological DMARDs in Systemic Rheumatic Diseases. <i>Handbook of Systemic Autoimmune Diseases</i> , 2018, 15, 161-182.	0.1	0
72	Controlled-release pregabalin in the treatment of fibromyalgia. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 617-623.	2.8	4

#	ARTICLE	IF	CITATIONS
73	A Review of Chronic Musculoskeletal Pain: Central and Peripheral Effects of Diclofenac. <i>Pain and Therapy</i> , 2018, 7, 163-177.	3.2	37
74	Prise en charge de lâ€™infection par le virus de lâ€™hÃ©patite B chez les patients atteints de polyarthrite rhumatoïde: conférence de consensus italienne. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2018, 85, 115-120.	0.0	0
75	Ankylosing Spondylitis Treatment after First Anti-TNF Drug Failure. <i>Israel Medical Association Journal</i> , 2018, 20, 119-122.	0.1	3
76	Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry. <i>Clinical Rheumatology</i> , 2017, 36, 753-761.	2.2	28
77	EULAR revised recommendations for the management of fibromyalgia. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 318-328.	0.9	880
78	Cardiac Imaging Techniques in Systemic Autoimmune Diseases. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, 14, 183-207.	0.1	0
79	New Cardiac Imaging Tools and Invasive Techniques in Systemic Autoimmune Diseases (Part II). <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, 14, 209-226.	0.1	0
80	Impact of Moving From a Widespread to Multisite Pain Definition on Other Fibromyalgia Symptoms. <i>Arthritis Care and Research</i> , 2017, 69, 1878-1886.	3.4	12
81	Infections in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2017, 29, 323-330.	4.3	34
82	Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis. <i>Joint Bone Spine</i> , 2017, 84, 525-530.	1.6	15
83	Subclinical atherosclerosis and history of cardiovascular events in Italian patients with rheumatoid arthritis. <i>Medicine (United States)</i> , 2017, 96, e8180.	1.0	21
84	Unresolved and critical issues in autoimmune rheumatic diseases. <i>Autoimmunity Reviews</i> , 2017, 16, 1093-1095.	5.8	4
85	The influence of fibromyalgia on achieving remission in patients with long-standing rheumatoid arthritis. <i>Rheumatology International</i> , 2017, 37, 2035-2042.	3.0	45
86	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis, etc.) <i>TJ ETQq0 0 0 rgBT, /Overlock 10 Tf 50 2</i>	3.8	107
87	OP0006â€¦Influence of autonomic nervous system dysfunction in the genesis of sleep disorders in fibromyalgia patients. , 2017, 35 Suppl 105, 74-80.		17
88	The clinical impact of Anti-DFS70 antibodies in undifferentiated connective tissue disease: case reports and a review of the literature. <i>Immunologic Research</i> , 2017, 65, 293-295.	2.9	19
89	Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study. <i>Immunologic Research</i> , 2017, 65, 419-422.	2.9	50
90	An update on emerging drugs for fibromyalgia treatment. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 357-367.	2.4	11

#	ARTICLE	IF	CITATIONS
91	The Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2127.	4.1	10
92	Measurement of Serum Klotho in Systemic Sclerosis. <i>Disease Markers</i> , 2017, 2017, 1-7.	1.3	7
93	Spondyloarthritis and Gastrointestinal Involvement. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, 13, 349-361.	0.1	0
94	A Proposed Serum Calprotectin IgG Cut-Off Level for Diagnosing Inflammatory Arthritis. <i>Current Rheumatology Reviews</i> , 2017, 13, 93-97.	0.8	7
95	Acute and chronic pain in orthopaedic and rheumatologic diseases: mechanisms and characteristics. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 105, 127-131.	0.8	2
96	Childhood adversities in patients with fibromyalgia: are they related to comorbid lifetime major depression?. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 105, 112-118.	0.8	4
97	Identifying the symptom and functional domains in patients with fibromyalgia: results of a cross-sectional Internet-based survey in Italy. <i>Journal of Pain Research</i> , 2016, 9, 279.	2.0	26
98	Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab. <i>Biologics: Targets and Therapy</i> , 2016, 10, 53.	3.2	17
99	Possible relationship between certolizumab pegol and arrhythmias: report of two cases. <i>Reumatismo</i> , 2016, 68, 104-108.	0.9	4
100	Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate. <i>Advances in Therapy</i> , 2016, 33, 1360-1373.	2.9	9
101	Safety of Abatacept in Rheumatoid Arthritis With Serologic Evidence of Past or Present Hepatitis B Virus Infection. <i>Arthritis Care and Research</i> , 2016, 68, 738-743.	3.4	48
102	Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic tools. <i>RMD Open</i> , 2016, 2, e000302.	3.8	57
103	Early clinical response predicts low disease activity at one year in rheumatoid arthritis patients on treatment with certolizumab in real-life settings. An appraisal of the Italian registry GISEA. <i>Joint Bone Spine</i> , 2016, 83, 721-725.	1.6	8
104	What are the dangers of biological therapy discontinuation or dose reduction strategies when treating rheumatoid arthritis?. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1403-1411.	3.1	7
105	Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability. <i>Clinical Rheumatology</i> , 2016, 35, 2649-2656.	2.2	19
106	The safety of pregabalin in the treatment of fibromyalgia. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1541-1548.	2.4	4
107	Hidden musculoskeletal involvement in inflammatory bowel disease: a multicenter ultrasound study. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 84.	1.9	13
108	Patient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS survey. <i>Arthritis Research and Therapy</i> , 2016, 18, 78.	3.5	52

#	ARTICLE	IF	CITATIONS
109	Novel pharmaceutical options for treating fibromyalgia. Expert Review of Clinical Pharmacology, 2016, 9, 559-565.	3.1	6
110	Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBcâ€“positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study. Journal of Rheumatology, 2016, 43, 869-874.	2.0	49
111	SERUM CALPROTECTIN LEVELS AS A MARKER OF ARTHRITIS: AN ITALIAN EXPERIENCE. Current Rheumatology Reviews, 2016, 12, 1-1.	0.8	2
112	One year in review 2016: fibromyalgia. Clinical and Experimental Rheumatology, 2016, 34, S145-9.	0.8	19
113	Early psoriatic arthritis: should we treat it in the same way as we treat rheumatoid arthritis?. International Journal of Clinical Rheumatology, 2015, 10, 399-408.	0.3	0
114	Antidrug antibodies against TNF-blocking agents: correlations between disease activity, hypersensitivity reactions, and different classes of immunoglobulins. Biologics: Targets and Therapy, 2015, 9, 7.	3.2	14
115	Clinical Comparison of QUANTA Flash dsDNA Chemiluminescent Immunoassay with Four Current Assays for the Detection of Anti-dsDNA Autoantibodies. Journal of Immunology Research, 2015, 2015, 1-8.	2.2	30
116	Efficacy and Safety of Pregabalin in Patients with Fibromyalgia and Comorbid Depression Taking Concurrent Antidepressant Medication: A Randomized, Placebo-controlled Study. Journal of Rheumatology, 2015, 42, 1237-1244.	2.0	31
117	Cardiovascular and autoimmune diseases in females: The role of microvasculature and dysfunctional endothelium. Atherosclerosis, 2015, 241, 259-263.	0.8	27
118	Measuring psoriatic disease in clinical practice. An expert opinion position paper. Autoimmunity Reviews, 2015, 14, 864-874.	5.8	25
119	Pain in systemic inflammatory rheumatic diseases. Best Practice and Research in Clinical Rheumatology, 2015, 29, 42-52.	3.3	25
120	Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Annals of the Rheumatic Diseases, 2015, 74, 979-984.	0.9	119
121	Serological epitope profile of anti-Ro52â€“positive patients with systemic autoimmune rheumatic diseases. Arthritis Research and Therapy, 2015, 17, 365.	3.5	16
122	The impact of pain on systemic rheumatic diseases. Best Practice and Research in Clinical Rheumatology, 2015, 29, 1-5.	3.3	12
123	The words of pain in complex regional pain syndrome. Best Practice and Research in Clinical Rheumatology, 2015, 29, 71-76.	3.3	12
124	Pain in systemic connective tissue diseases. Best Practice and Research in Clinical Rheumatology, 2015, 29, 53-62.	3.3	14
125	How to measure chronic pain: New concepts. Best Practice and Research in Clinical Rheumatology, 2015, 29, 164-186.	3.3	22
126	Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study. Rheumatology, 2015, 54, 792-797.	1.9	67

#	ARTICLE	IF	CITATIONS
127	Building bridges between doctors and patients: the design and pilot evaluation of a training session in argumentation for chronic pain experts. BMC Medical Education, 2015, 15, 89.	2.4	9
128	Pain management in cryoglobulinaemic syndrome. Best Practice and Research in Clinical Rheumatology, 2015, 29, 77-89.	3.3	6
129	Paradoxical Expansion of Th1 and Th17 Lymphocytes in Rheumatoid Arthritis Following Infliximab Treatment: a Possible Explanation for a Lack of Clinical Response. Journal of Clinical Immunology, 2015, 35, 550-557.	3.8	42
130	Significance of serum Il-9 levels in inflammatory bowel disease. International Journal of Immunopathology and Pharmacology, 2015, 28, 569-575.	2.1	29
131	Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: cause for concern?. Immunotherapy, 2015, 7, 353-361.	2.0	35
132	Psoriatic Arthritis Registries. Journal of rheumatology Supplement, The, 2015, 93, 30-32.	2.2	2
133	Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis. Journal of rheumatology Supplement, The, 2015, 93, 79-81.	2.2	9
134	The Prevalence of Fibromyalgia in the General Population: A Comparison of the American College of Rheumatology 1990, 2010, and Modified 2010 Classification Criteria. Arthritis and Rheumatology, 2015, 67, 568-575.	5.6	323
135	Differential Diagnosis of Vasovagal Syncope: Fibromyalgia. , 2015, , 213-221.		0
136	Position paper of Italian rheumatologists on the use of biosimilar drugs. Clinical and Experimental Rheumatology, 2015, 33, 1-4.	0.8	22
137	Relationship between sympathetic activity and pain intensity in fibromyalgia. Clinical and Experimental Rheumatology, 2015, 33, S53-7.	0.8	33
138	Doctorsâ€™ Insights into the Patient Perspective: A Qualitative Study in the Field of Chronic Pain. BioMed Research International, 2014, 2014, 1-6.	1.9	20
139	Costs of pain in Rheumatology. Reumatismo, 2014, 66, 103-107.	0.9	5
140	Physiopathology of pain in rheumatology. Reumatismo, 2014, 66, 4-13.	0.9	14
141	Pain in fibromyalgia and related conditions. Reumatismo, 2014, 66, 72-86.	0.9	24
142	Somatoform disorders and rheumatic diseases: from DSM-IV to DSM-V. Reumatismo, 2014, 66, 98-102.	0.9	2
143	Pain in rheumatoid arthritis: a critical review. Reumatismo, 2014, 66, 18-27.	0.9	47
144	Pain and systemic lupus erythematosus. Reumatismo, 2014, 66, 33-38.	0.9	24

#	ARTICLE	IF	CITATIONS
145	Pain in rheumatic diseases: how relevant is it?. <i>Reumatismo</i> , 2014, 66, 1-3.	0.9	3
146	High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register. <i>Clinical Rheumatology</i> , 2014, 33, 31-37.	2.2	10
147	Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1202-1210.	0.9	166
148	Rheumatic manifestations in inflammatory bowel disease. <i>Autoimmunity Reviews</i> , 2014, 13, 20-23.	5.8	61
149	Fibromyalgia in patients with axial spondyloarthritis: epidemiological profile and effect on measures of disease activity. <i>Rheumatology International</i> , 2014, 34, 1103-1110.	3.0	99
150	Autoimmunity and the Newer Biopharmaceuticals. , 2014, , 795-802.		1
151	Chronic inflammatory diseases: Do immunological patterns drive the choice of biotechnology drugs? A critical review. <i>Autoimmunity</i> , 2014, 47, 287-306.	2.6	16
152	Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register. <i>Joint Bone Spine</i> , 2014, 81, 508-512.	1.6	21
153	The 158V Fcγ3 receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 716-721.	0.9	52
154	Is atherosclerosis an autoimmune disease?. <i>BMC Medicine</i> , 2014, 12, 47.	5.5	122
155	Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis: Could it be the first step of the treatment?. <i>Autoimmunity Reviews</i> , 2014, 13, 49-53.	5.8	28
156	Prevalence of mixed cryoglobulinaemia syndrome and circulating cryoglobulins in a population-based survey: the Origgio study. <i>Autoimmunity Reviews</i> , 2014, 13, 609-614.	5.8	37
157	Immunity, autoimmunity and inflammatory bowel disease. <i>Autoimmunity Reviews</i> , 2014, 13, 1-2.	5.8	28
158	Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28 scores. <i>Joint Bone Spine</i> , 2014, 81, 37-40.	1.6	23
159	Anti-citrullinated peptide antibodies and rheumatoid factor isotypes in the diagnosis of rheumatoid arthritis: an assessment of combined tests. <i>Clinica Chimica Acta</i> , 2014, 436, 237-242.	1.1	22
160	New biological treatments for psoriatic arthritis. <i>Israel Medical Association Journal</i> , 2014, 16, 643-5.	0.1	4
161	Morphological distribution of IgA chains and CD15 receptors in colorectal polyp and adenocarcinoma specimens. <i>BMC Clinical Pathology</i> , 2013, 13, 8.	1.8	3
162	Different effects of biological drugs in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2013, 12, 575-579.	5.8	76

#	ARTICLE	IF	CITATIONS
163	Long-term safety of abatacept in patients with rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2013, 12, 1115-1117.	5.8	30
164	Reply. <i>Arthritis Care and Research</i> , 2013, 65, 2063-2063.	3.4	0
165	Infections during treatment with biological agents and possible treatment in clinical practice. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 193-195.	3.0	2
166	Silent cardiovascular involvement in patients with diffuse systemic sclerosis: a controlled cross-sectional study. <i>Arthritis Care and Research</i> , 2013, 65, 274-280.	3.4	40
167	The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers. <i>Arthritis and Rheumatism</i> , 2013, 65, 88-97.	6.7	22
168	Immunogenicity and autoimmunity during anti-TNF therapy. <i>Autoimmunity Reviews</i> , 2013, 12, 703-708.	5.8	167
169	Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 649-657.	3.0	41
170	Developing new classification criteria for diffuse idiopathic skeletal hyperostosis: back to square one. <i>Rheumatology</i> , 2013, 52, 326-330.	1.9	42
171	Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis. <i>Biologics: Targets and Therapy</i> , 2013, 7, 69.	3.2	31
172	No Correlations Between the Development of Specific IgA and IgM Antibodies Against Anti-TNF Blocking Agents, Disease Activity and Adverse Side Reactions in Patients with Rheumatoid Arthritis. <i>Open Rheumatology Journal</i> , 2013, 7, 75-80.	0.2	7
173	Efficacy of ketoprofen vs. ibuprofen and diclofenac: a systematic review of the literature and meta-analysis. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 731-8.	0.8	18
174	Psychometric characteristics of the Italian version of the revised Fibromyalgia Impact Questionnaire using classical test theory and Rasch analysis. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, S41-9.	0.8	16
175	Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 857-63.	0.8	32
176	CC chemokine receptor 5 polymorphism in Italian patients with Behcet's disease. <i>Rheumatology</i> , 2012, 51, 2141-2145.	1.9	12
177	Why wait? Explaining delays in seeking therapy for early arthritis. <i>Nature Reviews Rheumatology</i> , 2012, 8, 190-191.	8.0	4
178	Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry. <i>Autoimmunity Reviews</i> , 2012, 12, 225-229.	5.8	146
179	Interleukin 6 Blockade: Tocilizumab in Psoriatic Arthritis. <i>Journal of rheumatology Supplement</i> , The, 2012, 89, 97-99.	2.2	23
180	Identification of the Clinical Features Distinguishing Psoriatic Arthritis and Fibromyalgia. <i>Journal of Rheumatology</i> , 2012, 39, 849-855.	2.0	94

#	ARTICLE	IF	CITATIONS
181	Unusual B cell morphology in inflammatory bowel disease. <i>Pathology Research and Practice</i> , 2012, 208, 387-391.	2.3	3
182	Detection of preclinical impairment of myocardial function in rheumatoid arthritis patients with short disease duration by speckle tracking echocardiography. <i>International Journal of Cardiology</i> , 2012, 160, 8-14.	1.7	41
183	Rituximab treatment for Sjogren syndrome-associated non-Hodgkin's lymphoma: case series. <i>Rheumatology International</i> , 2012, 32, 3281-3284.	3.0	7
184	Barriers to Pain Management. <i>Clinical Drug Investigation</i> , 2012, 32, 11-19.	2.2	53
185	The Appropriate Treatment of Chronic Pain. <i>Clinical Drug Investigation</i> , 2012, 32, 21-33.	2.2	70
186	Adverse Effects Associated with Non-opioid and Opioid Treatment in Patients with Chronic Pain. <i>Clinical Drug Investigation</i> , 2012, 32, 53-63.	2.2	149
187	The Management of Chronic Pain in Important Patient Subgroups. <i>Clinical Drug Investigation</i> , 2012, 32, 35-44.	2.2	33
188	Biomarkers of Good EULAR Response to the B Cell Depletion Therapy in All Seropositive Rheumatoid Arthritis Patients: Clues for the Pathogenesis. <i>PLoS ONE</i> , 2012, 7, e40362.	2.5	34
189	Update on fibromyalgia. <i>Italian Journal of Medicine</i> , 2012, , 14-20.	0.3	0
190	Twelve years' experience with etanercept in the treatment of rheumatoid arthritis: how it has changed clinical practice. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 213-222.	3.0	8
191	The CC homozygosis of the γ 174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2012, 11, 315-320.	5.8	43
192	Is fibromyalgia a discrete entity?. <i>Autoimmunity Reviews</i> , 2012, 11, 585-588.	5.8	30
193	Early treatment in early undifferentiated arthritis. <i>Autoimmunity Reviews</i> , 2012, 11, 589-592.	5.8	31
194	Controversies in rheumatism and autoimmunity. <i>Autoimmunity Reviews</i> , 2012, 11, 555-557.	5.8	6
195	Alexithymia and psychological distress in fibromyalgia: prevalence and relation with quality of life. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 70-7.	0.8	36
196	Old and new criteria for the classification and diagnosis of fibromyalgia: comparison and evaluation. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 3-9.	0.8	22
197	Overactive lifestyle in patients with fibromyalgia as a core feature of bipolar spectrum disorder. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 122-8.	0.8	12
198	Dysfunctional syndromes and fibromyalgia: a 2012 critical digest. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 143-51.	0.8	19

#	ARTICLE	IF	CITATIONS
199	Echocardiographic approach in systemic autoimmune diseases. <i>Journal of Cardiovascular Echography</i> , 2011, 21, 152-156.	0.4	0
200	Switching rheumatoid arthritis treatments: An update. <i>Autoimmunity Reviews</i> , 2011, 10, 397-403.	5.8	33
201	Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. <i>Autoimmunity Reviews</i> , 2011, 10, 444-454.	5.8	186
202	Chronic widespread pain in the spectrum of rheumatological diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 165-171.	3.3	100
203	Clinimetric evaluations of patients with chronic widespread pain. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 249-270.	3.3	18
204	Pharmacotherapy of fibromyalgia. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 285-297.	3.3	56
205	Multidisciplinary approach to fibromyalgia: What is the teaching?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 311-319.	3.3	49
206	Chronic widespread pain or fibromyalgia? That is the question. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 131-132.	3.3	9
207	Fibromyalgia and Sleep. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 227-239.	3.3	45
208	Chronic widespread pain: From peripheral to central evolution. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 133-139.	3.3	44
209	Cardiovascular injury in systemic autoimmune diseases: an update. <i>Internal and Emergency Medicine</i> , 2011, 6, 99-102.	2.0	5
210	B Lymphocyte intestinal homing in inflammatory bowel disease. <i>BMC Immunology</i> , 2011, 12, 71.	2.2	17
211	Coronary Flow Reserve and Asymmetric Dimethylarginine Levels: New Measurements for Identifying Subclinical Atherosclerosis in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 1661-1664.	2.0	46
212	Cost Effectiveness Analysis of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. A Systematic Review Literature. <i>International Journal of Rheumatology</i> , 2011, 2011, 1-6.	1.6	32
213	Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 712-714.	0.9	27
214	Childhood Parental Loss and Bipolar Spectrum in Obese Bariatric Surgery Candidates. <i>International Journal of Psychiatry in Medicine</i> , 2011, 41, 155-171.	1.8	17
215	Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, S7-14.	0.8	23
216	Efficacy and Safety of Anti-Tumour Necrosis Factor in Elderly Patients with Rheumatoid Arthritis: An Observational Study. <i>Clinical Reviews in Allergy and Immunology</i> , 2010, 38, 90-96.	6.5	63

#	ARTICLE	IF	CITATIONS
217	Tumour necrosis factor antagonist therapy and cancer development: Analysis of the LORHEN registry. <i>Autoimmunity Reviews</i> , 2010, 9, 175-180.	5.8	80
218	The heart in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2010, 9, 414-418.	5.8	32
219	Switching TNF-alpha antagonists in rheumatoid arthritis: The experience of the LORHEN registry. <i>Autoimmunity Reviews</i> , 2010, 9, 465-469.	5.8	38
220	From endothelial dysfunction to atherosclerosis. <i>Autoimmunity Reviews</i> , 2010, 9, 830-834.	5.8	432
221	The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. <i>Autoimmunity Reviews</i> , 2010, 9, 835-839.	5.8	75
222	Usefulness of cardiovascular biomarkers and cardiac imaging in systemic rheumatic diseases. <i>Autoimmunity Reviews</i> , 2010, 9, 845-848.	5.8	14
223	Cardiac involvement in systemic rheumatic diseases: An update. <i>Autoimmunity Reviews</i> , 2010, 9, 849-852.	5.8	65
224	Safety of tumor necrosis factor \pm blockers in hepatitis B virus occult carriers (hepatitis B surface) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 4 <i>Research</i> , 2010, 62, 749-754.	3.4	110
225	Neuroendocrine therapy of fibromyalgia syndrome: an update. <i>Annals of the New York Academy of Sciences</i> , 2010, 1193, 91-97.	3.8	18
226	Psoriatic arthritis. <i>Annals of the New York Academy of Sciences</i> , 2010, 1193, 176-178.	3.8	2
227	Anti- TNF therapy restores the hypothalamic-pituitary-adrenal axis. <i>Annals of the New York Academy of Sciences</i> , 2010, 1193, 179-181.	3.8	5
228	IgG anti-pentraxin 3 antibodies in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1704-1710.	0.9	56
229	Is It Antiphospholipid Syndrome?. <i>International Journal of Rheumatology</i> , 2010, 2010, 1-4.	1.6	0
230	RESEARCH: Effects of Long-Term Disease-Modifying Antirheumatic Drugs on Endothelial Function in Patients with Early Rheumatoid Arthritis. <i>Cardiovascular Therapeutics</i> , 2010, 28, e53-64.	2.5	79
231	Resistant Cases of Psoriatic Arthritis: How to Manage Them. <i>Journal of rheumatology Supplement</i> , The, 2009, 83, 73-75.	2.2	9
232	Extraspinal manifestations of diffuse idiopathic skeletal hyperostosis. <i>Rheumatology</i> , 2009, 48, 1478-1481.	1.9	130
233	TNF- \pm Antagonist Survival Rate in a Cohort of Rheumatoid Arthritis Patients Observed under Conditions of Standard Clinical Practice. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 837-846.	3.8	130
234	Central motor control failure in fibromyalgia: a surface electromyography study. <i>BMC Musculoskeletal Disorders</i> , 2009, 10, 78.	1.9	31

#	ARTICLE	IF	CITATIONS
235	Cardiovascular involvement in systemic autoimmune diseases. <i>Autoimmunity Reviews</i> , 2009, 8, 281-286.	5.8	103
236	Anti-TNF \pm therapy in a cohort of rheumatoid arthritis patients: Clinical outcomes. <i>Autoimmunity Reviews</i> , 2009, 8, 260-265.	5.8	35
237	Serious infections during anti-TNF \pm treatment in rheumatoid arthritis patients. <i>Autoimmunity Reviews</i> , 2009, 8, 266-273.	5.8	148
238	Treatment of rheumatoid arthritis with anti-TNF-alpha agents: A reappraisal. <i>Autoimmunity Reviews</i> , 2009, 8, 274-280.	5.8	101
239	Predicting response to anti-TNF treatment in rheumatoid arthritis patients. <i>Autoimmunity Reviews</i> , 2009, 8, 431-437.	5.8	50
240	Non-invasive assessment of coronary flow reserve and ADMA levels: a case-control study of early rheumatoid arthritis patients. <i>Rheumatology</i> , 2009, 48, 834-839.	1.9	94
241	Development and validation of the self-administered Fibromyalgia Assessment Status: a disease-specific composite measure for evaluating treatment effect. <i>Arthritis Research and Therapy</i> , 2009, 11, R125.	3.5	48
242	Combined therapeutic approach: Inflammatory bowel diseases and peripheral or axial arthritis. <i>World Journal of Gastroenterology</i> , 2009, 15, 2469.	3.3	19
243	Anti-cytokine antibodies for rheumatic diseases. <i>Current Opinion in Investigational Drugs</i> , 2009, 10, 1204-11.	2.3	21
244	Increased cortisol relative to adrenocorticotrophic hormone predicts improvement during anti-tumor necrosis factor therapy in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2008, 58, 976-984.	6.7	37
245	Infections, rheumatism and autoimmunity: The conflicting relationship between humans and their environment. <i>Autoimmunity Reviews</i> , 2008, 8, 1-4.	5.8	67
246	Etiology of fibromyalgia: The possible role of infection and vaccination. <i>Autoimmunity Reviews</i> , 2008, 8, 41-43.	5.8	116
247	Exploring the complex relationships between infections and autoimmunity. <i>Autoimmunity Reviews</i> , 2008, 8, 89-91.	5.8	33
248	Treatment Strategy in Fibromyalgia Syndrome: Where Are We Now?. <i>Seminars in Arthritis and Rheumatism</i> , 2008, 37, 353-365.	3.4	89
249	Amputation of Digits or Limbs in Patients with Antiphospholipid Syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2008, 38, 124-131.	3.4	37
250	Anti-cyclic citrullinated peptide antibodies in primary Sjogren's syndrome may be associated with non-erosive synovitis. <i>Arthritis Research and Therapy</i> , 2008, 10, R51.	3.5	64
251	Chapter 27 Modulation of Hormone Axes by Anti-TNF Therapy. <i>Handbook of Systemic Autoimmune Diseases</i> , 2008, 9, 301-308.	0.1	3
252	EULAR evidence-based recommendations for the management of fibromyalgia syndrome. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 536-541.	0.9	639

#	ARTICLE	IF	CITATIONS
253	Organ specific-autoantibodies: Their role as markers and predictors of disease. <i>Autoimmunity</i> , 2008, 41, 1-10.	2.6	4
254	Organ-specific autoantibodies in patients with rheumatoid arthritis treated with adalimumab: A prospective long-term follow-up. <i>Autoimmunity</i> , 2008, 41, 87-91.	2.6	9
255	Anti-thyroid antibodies and thyroid dysfunction in rheumatoid arthritis: Prevalence and clinical value. <i>Autoimmunity</i> , 2008, 41, 111-115.	2.6	53
256	Anti-polymer antibodies are inversely correlated with pain and fatigue severity in patients with fibromyalgia syndrome. <i>Autoimmunity</i> , 2008, 41, 74-79.	2.6	9
257	Autoantibody production in patients treated with anti-TNF- α . <i>Expert Review of Clinical Immunology</i> , 2008, 4, 275-280.	3.0	40
258	Validation of the reflux disease questionnaire for an Italian population of patients with gastroesophageal reflux disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 187-190.	1.6	14
259	Diagnosis of cardiac involvement in systemic autoimmune diseases. <i>Expert Review of Clinical Immunology</i> , 2007, 3, 839-843.	3.0	0
260	The genetics of fibromyalgia syndrome. <i>Pharmacogenomics</i> , 2007, 8, 67-74.	1.3	125
261	AUTOIMMUNITY AND THE NEWER BIOPHARMACEUTICALS. , 2007, , 783-791.		0
262	What is the role of rituximab in the treatment of rheumatoid arthritis?. <i>Autoimmunity Reviews</i> , 2007, 6, 553-558.	5.8	30
263	Potential target of infliximab in autoimmune and inflammatory diseases. <i>Autoimmunity Reviews</i> , 2007, 6, 529-536.	5.8	50
264	OxLDL/ β 2GPI α anti-oxLDL/ β 2GPI complex and atherosclerosis in SLE patients. <i>Autoimmunity Reviews</i> , 2007, 7, 52-58.	5.8	50
265	Antigen Preparation for Immunological Studies in Systemic Autoimmune Diseases. <i>Annals of the New York Academy of Sciences</i> , 2007, 1109, 193-202.	3.8	1
266	Preclinical Impairment of Coronary Flow Reserve in Patients with Rheumatoid Arthritis. <i>Annals of the New York Academy of Sciences</i> , 2007, 1108, 392-397.	3.8	19
267	Mycophenolate Mofetil in Lupus Glomerulonephritis: Effectiveness and Tolerability. <i>Annals of the New York Academy of Sciences</i> , 2007, 1110, 516-524.	3.8	11
268	Biology and therapy of fibromyalgia. Genetic aspects of fibromyalgia syndrome. <i>Arthritis Research and Therapy</i> , 2006, 8, 218.	3.5	114
269	Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. <i>Arthritis Research and Therapy</i> , 2006, 8, R3.	3.5	105
270	Calcium Deposition and Associated Chronic Diseases (Atherosclerosis, Diffuse Idiopathic Skeletal) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.9	47

#	ARTICLE	IF	CITATIONS
271	Long-Term Prognosis and Causes of Death in Systemic Lupus Erythematosus. <i>American Journal of Medicine</i> , 2006, 119, 700-706.	1.5	278
272	Increased Neural Sympathetic Activation in Fibromyalgia Syndrome. <i>Annals of the New York Academy of Sciences</i> , 2006, 1069, 109-117.	3.8	62
273	Estrogens in Pregnancy and Systemic Lupus Erythematosus. <i>Annals of the New York Academy of Sciences</i> , 2006, 1069, 247-256.	3.8	63
274	Pyogenic Arthritis of the Facet Joints: A Growing Problem for Patients, A Growing Concern for Clinicians. <i>Seminars in Arthritis and Rheumatism</i> , 2006, 35, 269-270.	3.4	0
275	Tumor necrosis factor- α neutralizing therapies improve altered hormone axes: An alternative mode of antiinflammatory action. <i>Arthritis and Rheumatism</i> , 2006, 54, 2039-2046.	6.7	53
276	Influence of coping skills on health-related quality of life in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006, 55, 427-433.	6.7	43
277	Anti-TNF antibody treatment improves glucocorticoid induced insulin-like growth factor 1 (IGF1) resistance without influencing myoglobin and IGF1 binding proteins 1 and 3. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 301-305.	0.9	38
278	Rheumatoid Arthritis and the Skin. <i>Handbook of Systemic Autoimmune Diseases</i> , 2006, , 161-183.	0.1	0
279	Tumour necrosis factor α is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 545-548.	0.9	55
280	Increase of sympathetic outflow measured by neuropeptide Y and decrease of the hypothalamic-pituitary-adrenal axis tone in patients with systemic lupus erythematosus and rheumatoid arthritis: another example of uncoupling of response systems. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 51-56.	0.9	103
281	Polymyositis-dermatomyositis and infections. <i>Autoimmunity</i> , 2006, 39, 191-196.	2.6	45
282	Systemic Lupus Erythematosus, Atherosclerosis, and Autoantibodies. <i>Annals of the New York Academy of Sciences</i> , 2005, 1051, 351-361.	3.8	46
283	Autoimmunity and Anti-TNF- α Agents. <i>Annals of the New York Academy of Sciences</i> , 2005, 1051, 559-569.	3.8	150
284	Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 453-461.	3.7	31
285	Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review. <i>Autoimmunity Reviews</i> , 2005, 4, 144-152.	5.8	42
286	The role of echocardiographic techniques in connective tissue diseases. <i>Autoimmunity Reviews</i> , 2005, 4, 171-177.	5.8	12
287	TNF- α , rheumatoid arthritis, and heart failure: a rheumatological dilemma. <i>Autoimmunity Reviews</i> , 2005, 4, 153-161.	5.8	118
288	Five-Year Follow-Up by Transesophageal Echocardiographic Studies in Primary Antiphospholipid Syndrome. <i>American Journal of Cardiology</i> , 2005, 96, 574-579.	1.6	72

#	ARTICLE	IF	CITATIONS
289	Osteoarthritis: An Overview of the Disease and Its Treatment Strategies. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 35, 1-10.	3.4	316
290	The Characteristics of Symptomatic Osteoarthritis in General and Specialist Practice in Italy: Design and Methods of the AMICA Study. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 35, 11-16.	3.4	5
291	Clinical Presentation of Osteoarthritis in General Practice: Determinants of Pain in Italian Patients in the AMICA Study. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 35, 17-23.	3.4	53
292	Analysis of Pharmacologic and Nonpharmacologic Prescription Patterns of General Practitioners and Specialists in the AMICA Study. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 35, 24-30.	3.4	11
293	Comorbid Conditions in the AMICA Study Patients: Effects on the Quality of Life and Drug Prescriptions by General Practitioners and Specialists. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 35, 31-37.	3.4	64
294	Do Physicians Treat Symptomatic Osteoarthritis Patients Properly? Results of the AMICA Experience. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 35, 38-42.	3.4	35
295	An open, randomized comparison study of cyclosporine, cyclosporine + methotrexate and cyclosporine + hydroxychloroquine in the treatment of early severe rheumatoid arthritis. <i>Rheumatology International</i> , 2005, 25, 15-22.	3.0	39
296	Heart, rheumatism and autoimmunity: an old intriguing link. <i>Lupus</i> , 2005, 14, 643-645.	1.6	4
297	No change of serum levels of leptin and adiponectin during anti-tumour necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2005, 65, 970-971.	0.9	60
298	Tumor necrosis factor- α , biologic agents and cardiovascular risk. <i>Lupus</i> , 2005, 14, 780-784.	1.6	65
299	Anti-tumour necrosis factor antibody treatment does not change serum levels of cortisol binding globulin in patients with rheumatoid arthritis but it increases androstenedione relative to cortisol. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 1353-1356.	0.9	8
300	Thrombotic Risk Factors In Primary Antiphospholipid Syndrome. <i>Stroke</i> , 2005, 36, 1490-1494.	2.0	71
301	Behçet's disease and cardiovascular involvement. <i>Lupus</i> , 2005, 14, 723-726.	1.6	93
302	Environment and systemic lupus erythematosus: An overview. <i>Autoimmunity</i> , 2005, 38, 465-472.	2.6	85
303	Cardiac imaging techniques in systemic autoimmune diseases. <i>Lupus</i> , 2005, 14, 727-731.	1.6	27
304	Cardiac involvement in systemic lupus erythematosus. <i>Lupus</i> , 2005, 14, 683-686.	1.6	305
305	Primary and secondary autoimmune neutropenia. <i>Arthritis Research and Therapy</i> , 2005, 7, 208.	3.5	146
306	Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis. <i>Arthritis Research</i> , 2005, 7, R250.	2.0	37

#	ARTICLE	IF	CITATIONS
307	Sex hormone concentrations in patients with rheumatoid arthritis are not normalized during 12 weeks of anti-tumor necrosis factor therapy. <i>Journal of Rheumatology</i> , 2005, 32, 1253-8.	2.0	24
308	Abnormalities of cardiovascular neural control and reduced orthostatic tolerance in patients with primary fibromyalgia. <i>Journal of Rheumatology</i> , 2005, 32, 1787-93.	2.0	112
309	Introduction: Osteoarthritis in the Third Millennium: A New Era for an Old Disease?. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 34, 1-2.	3.4	2
310	Osteoarthritis of the Spine. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 34, 38-43.	3.4	16
311	Hand Osteoarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 34, 47-52.	3.4	17
312	Physical and Rehabilitative Approaches in Osteoarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 34, 62-69.	3.4	8
313	The Italian version of the Fibrofatiigue Scale, a reliable tool for the evaluation of fibromyalgia symptoms. <i>Journal of Psychosomatic Research</i> , 2004, 56, 213-216.	2.6	13
314	New developments in our understanding of DISH (diffuse idiopathic skeletal hyperostosis). <i>Current Opinion in Rheumatology</i> , 2004, 16, 287-292.	4.3	139
315	Cyclic alternating pattern: a new marker of sleep alteration in patients with fibromyalgia?. <i>Journal of Rheumatology</i> , 2004, 31, 1193-9.	2.0	83
316	Infliximab-induced lupus in Crohn's disease: a case report. <i>Digestive and Liver Disease</i> , 2003, 35, 814-817.	0.9	58
317	Inflammatory bowel disease versus irritable bowel syndrome: a hospital-based, case-control study of disease impact on quality of life. <i>Scandinavian Journal of Gastroenterology</i> , 2003, 38, 1031-1038.	1.5	114
318	Cardiac Imaging Techniques in Systemic Autoimmune Diseases. <i>Handbook of Systemic Autoimmune Diseases</i> , 2003, , 107-119.	0.1	2
319	Correlation of the score for subjective pain with physical disability, clinical and radiographic scores in recent onset rheumatoid arthritis. <i>BMC Musculoskeletal Disorders</i> , 2002, 3, 18.	1.9	43
320	Long-term safety and efficacy of low-dose cyclosporin A in severe psoriatic arthritis. <i>Rheumatology International</i> , 2002, 21, 234-238.	3.0	37
321	Quantitative evaluation of regional left ventricular wall motion using color kinesis after percutaneous transluminal myocardial revascularization. <i>American Journal of Cardiology</i> , 2001, 87, 896-898.	1.6	1
322	Visceral Hypersensitivity Is Not a Feature of Fibromyalgia Syndrome. <i>Journal of Musculoskeletal Pain</i> , 2001, 9, 47-55.	0.3	5
323	Diet therapy for rheumatoid arthritis: A controlled double-blind study of two different dietary regimens. <i>Scandinavian Journal of Rheumatology</i> , 2000, 29, 302-307.	1.1	23
324	A Double-Blind Crossover Study of Two Cyclobenzaprine Regimens in Primary Fibromyalgia Syndrome. <i>Journal of International Medical Research</i> , 1993, 21, 74-80.	1.0	49

#	ARTICLE	IF	CITATIONS
325	Fibromyalgia: one year in review 2022. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	22
326	Concerns about the taxonomy, definition and coding of fibromyalgia syndrome in ICD-11: the potential for negative consequences for patient care and research. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	0